Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR3A | P46098 | 2/20 | 0.53 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.53 |
| ▸ | HTR3E | A5X5Y0 | 1/20 | 0.53 |
| ▸ | HTR3B | O95264 | 1/20 | 0.53 |
| ▸ | HTR5A | P47898 | 1/20 | 0.53 |
| ▸ | HTR3D | Q70Z44 | 1/20 | 0.53 |
| ▸ | HTR3C | Q8WXA8 | 1/20 | 0.53 |
| ▸ | CHRNB2 | P17787 | 2/20 | 0.49 |
| ▸ | CHRNA4 | P43681 | 2/20 | 0.49 |
| ▸ | DPP4 | P27487 | 2/20 | 0.43 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.43 |
| ▸ | CHRNB4 | P30926 | 3/20 | 0.41 |
| ▸ | CHRNA3 | P32297 | 3/20 | 0.41 |
| ▸ | GHSR | Q92847 | 3/20 | 0.41 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.40 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3541006 | 0.83 | CHRNB2 (0.45) | HTR3ASIGMAR1HTR3EHTR3BHTR5A | |
| SCHEMBL3547293 | 0.81 | HTR1A (0.55) | HTR3ASIGMAR1HTR3EHTR3BHTR3D | |
| SCHEMBL19852275 | 0.77 | CHRNB2 (0.62) | HTR3ASIGMAR1HTR3EHTR3BHTR3D | |
| SCHEMBL19839303 | 0.77 | CHRNB2 (0.62) | HTR3ASIGMAR1HTR3EHTR3BHTR3D | |
| SCHEMBL22728500 | 0.77 | HTR3A (0.63) | HTR3ASIGMAR1HTR3EHTR3BHTR5A | |
| SCHEMBL6998143 | 0.77 | HTR3A (0.53) | HTR3ASIGMAR1HTR3EHTR3BHTR5A | |
| SCHEMBL22721059 | 0.76 | BPTF (0.62) | HTR3ASIGMAR1HTR3EHTR3BHTR5A | |
| SCHEMBL6620585 | 0.74 | CHRNB2 (0.57) | CHRNB2CHRNA4DPP4CHRNB4CHRNA3 | |
| SCHEMBL22721111 | 0.72 | HTR3A (0.62) | HTR3ASIGMAR1HTR3EHTR3BHTR5A | |
| SCHEMBL6620860 | 0.72 | CHRNB2 (0.53) | CHRNB2CHRNA4CHRNB4CHRNA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080280882-A1 | Novel Substituted Diazabicyclo Derivatives and Their Use as Monoamine Neurotransmitter Re-Uptake Inhibitors | NEUROSEARCH A/S (DK) | 2008-11-13 | — | — | US | claimed |
| EP-1178047-B1 | Diazabicyclooctane derivatives and therapeutic uses thereof | PFIZER PROD INC (US) | 2004-02-25 | — | — | EP | claimed |
| US-6531468-B2 | Inhibiting serotonin reuptake in the central nervous system of a mammal | PFIZER INC | 2003-03-11 | — | — | US | claimed |
| US-20020068748-A1 | Diazabicyclooctane derivatives and therapeutic uses thereof | PFIZER INC. | 2002-06-06 | — | — | US | claimed |
| EP-1178047-A1 | Diazabicyclooctane derivatives and therapeutic uses thereof | Pfizer Products Inc. (US) | 2002-02-06 | — | — | EP | claimed |
| US-7704991-B2 | Substituted diazabicyclo derivatives and their use as monoamine neurotransmitter re-uptake inhibitors | NEUROSEARCH A/S (DK) | 2010-04-27 | — | — | US | disclosed |
| US-20080280882-A1 | Novel Substituted Diazabicyclo Derivatives and Their Use as Monoamine Neurotransmitter Re-Uptake Inhibitors | NEUROSEARCH A/S (DK) | 2008-11-13 | — | — | US | disclosed |
| EP-1869050-A1 | NOVEL SUBSTITUTED DIAZABICYCLO DERIVATIVES AND THEIR USE AS MONOAMINE NEUROTRANSMITTER RE-UPTAKE INHIBITORS | NEUROSEARCH A/S (DK) | 2007-12-26 | — | — | EP | disclosed |
| WO-2006106090-A1 | NOVEL SUBSTITUTED DIAZABICYCLO DERIVATIVES AND THEIR USE AS MONOAMINE NEUROTRANSMITTER RE-UPTAKE INHIBITORS | NEUROSEARCH A/S (DK) | 2006-10-12 | — | — | WO | disclosed |
| EP-1178047-B1 | Diazabicyclooctane derivatives and therapeutic uses thereof | PFIZER PROD INC (US) | 2004-02-25 | — | — | EP | disclosed |
| US-6531468-B2 | Inhibiting serotonin reuptake in the central nervous system of a mammal | PFIZER INC | 2003-03-11 | — | — | US | disclosed |
| US-20020068748-A1 | Diazabicyclooctane derivatives and therapeutic uses thereof | PFIZER INC. | 2002-06-06 | — | — | US | disclosed |
| EP-1178047-A1 | Diazabicyclooctane derivatives and therapeutic uses thereof | Pfizer Products Inc. (US) | 2002-02-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020068748-A1 | Diazabicyclooctane derivatives and therapeutic uses thereof | CNR1, CBR1, CLIC1 | HTR3A 1365/4885SIGMAR1 174/4885HTR3E 1458/4885 |
| US-20080280882-A1 | Novel Substituted Diazabicyclo Derivatives and Their Use as Monoamine Neurotransmitter Re-Uptake Inhibitors | SLC18A2, SLC6A2, SLC6A3 | HTR3A 80/4885SIGMAR1 138/4885HTR3E 162/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.